All Drugs for Neglected Diseases initiative articles
-
NewsNew treatment for cryptococcal meningitis enters Phase II trial
Cryptococcal meningitis, the second-leading cause of HIV-related deaths, is expected to rise as access to care weakens and advanced HIV disease (previously called AIDS) increases.
-
NewsPromising patient-friendly oral drug against visceral leishmaniasis enters Phase II clinical trial in Ethiopia
The new molecule has the potential to revolutionize treatment for the deeply neglected and hard-to-treat disease, as the Eastern Africa region charts the way to its elimination.
-
NewsStudy of simple acoziborole regime raises hope for elimination of sleeping sickness in Africa
The Drugs for Neglected Diseases initiative (DNDi) and Sanofi have announced treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigational treatment for sleeping sickness.